Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers

Reuters

Sep 15

Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers

Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule (UTD2). The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73152) on September 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567119284"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567119284\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567119284?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567119284","market":"us","top_or_hot":-1,"title":"Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule (UTD2). The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73152) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-15 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule (UTD2). The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73152) on September 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL7sPw5y:1","article_id":"2567119284","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567119284","pubTimestamp":1757937696,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule . The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02563":"华昊中天医药-B"},"translate_title":"Biostar Pharma启动Utidelone胶囊靶向胃癌和卵巢癌II/III期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02563":0.9},"content_text":"Biostar Pharma Initiates Phase II/III Clinical Trials for Utidelone Capsule Targeting Gastric and Ovarian Cancers\n    \n\n        Biostar Pharma, the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd., has announced the initiation of two phase II/III multiregional clinical trials for the Utidelone Capsule (UTD2). The trials focus on the first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma and the treatment for platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The first patients were dosed on September 11 and September 12, 2025, respectively. Utidelone is noted for its higher oral bioavailability and lower risk of cross-resistance compared to taxanes, which enhances its convenience and potential in combination therapies. The company has not yet presented results from these ongoing trials.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijing Biostar Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN73152) on September 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}